TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $631,343 | -41.8% | 70,620 | 0.0% | 0.00% | – |
Q2 2023 | $1,084,723 | -18.7% | 70,620 | +19.0% | 0.00% | -100.0% |
Q1 2023 | $1,334,107 | +6.9% | 59,320 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1,247,500 | -14.7% | 59,320 | -0.0% | 0.00% | 0.0% |
Q3 2022 | $1,462,000 | +1.7% | 59,333 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $1,438,000 | -6.0% | 59,333 | +0.0% | 0.00% | 0.0% |
Q1 2022 | $1,529,000 | -16.8% | 59,320 | +0.2% | 0.00% | 0.0% |
Q4 2021 | $1,838,000 | +28.0% | 59,220 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $1,436,000 | +54.9% | 59,220 | -6.8% | 0.00% | – |
Q2 2021 | $927,000 | -73.6% | 63,520 | -54.8% | 0.00% | -100.0% |
Q1 2021 | $3,513,000 | +102.9% | 140,680 | +121.5% | 0.00% | +100.0% |
Q4 2020 | $1,731,000 | – | 63,520 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |